

Title (en)  
RECOMBINANT BPI-BASED AND LBP-BASED PROTEINS, NUCLEIC ACID MOLECULES ENCODING SAME, METHODS OF PRODUCING SAME, AND USES THEREOF

Title (de)  
REKOMBINANTE, AUF BPI UND LBP BASIERENDE PROTEINE, DIE FÜR SIE KODIERENDEN NUKLEINSÄUREN, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG

Title (fr)  
PROTEINES DE RECOMBINAISON DE TYPE AUGMENTANT LA PERMEABILITE BACTERICIDE (BPI) ET DE TYPE FIXANT LE LIPOSACCHARIDE (LBD), MOLECULES CODANT POUR CES PROTEINES, LEURS PROCEDES DE PRODUCTION ET LEURS UTILISATIONS

Publication  
**EP 0760849 A4 19961202 (EN)**

Application  
**EP 94917901 A 19940429**

Priority  
• US 9404709 W 19940429  
• US 5629293 A 19930430  
• US 16571793 A 19931210

Abstract (en)  
[origin: WO9425476A1] The subject invention provides recombinant nucleic acid molecules which encode a BPI variant, an LBP variant, an LBP-BPI chimera, a BPI-IgG chimera, an LBP-IgG chimera, or an LBP-BPI-IgG chimera, and the proteins encoded thereby. The subject invention further provides host vector systems for the production of a BPI variant, LBP variant, LBP-BPI chimera, BPI-IgG chimera, LBP-IgG chimera, or LBP-BPI-IgG chimera, and methods of using same for producing said proteins. The subject invention provides a pharmaceutical composition, which comprises a therapeutically effective amount of a BPI variant, an LBP variant, an LBP-BPI chimera, a BPI-IgG chimera, an LBP-IgG chimera, or an LBP-BPI-IgG chimera, and a pharmaceutically acceptable carrier, and the method of using same to treat a subject suffering from an endotoxin-related disorder. Finally, the subject invention provides a method of preventing an endotoxin-related disorder in a subject, which comprises administering to the subject a prophylactically effective amount of a BPI variant, an LBP variant, an LBP-BPI chimera, a BPI-IgG chimera, an LBP-IgG chimera.

IPC 1-7  
**C12N 15/12**; **C12N 15/62**; **C12N 15/85**; **C07K 14/00**; **C12N 5/16**; **A61K 39/00**

IPC 8 full level  
**C12N 1/19** (2006.01); **C07K 14/47** (2006.01); **A61K 38/00** (2006.01); **C12R 1/84** (2006.01)

CPC (source: EP)  
**C07K 14/47** (2013.01); **C07K 14/4742** (2013.01); **A61K 38/00** (2013.01); **C07K 2319/33** (2013.01); **C07K 2319/55** (2013.01)

Citation (search report)  
• [XY] WO 9203535 A1 19920305 - INCYTE PHARMA INC [US]  
• [XY] WO 9305797 A1 19930401 - INCYTE PHARMA INC [US]  
• [XY] WO 9306228 A1 19930401 - INCYTE PHARMA INC [US]  
• [X] WO 9009183 A1 19900823 - INVITRON CORP [US]  
• [Y] EP 0464533 A1 19920108 - BEHRINGWERKE AG [DE], et al  
• [PX] WO 9323434 A2 19931125 - XOMA CORP [US]  
• [T] AU-YOUNG J ET AL.: "A novel LBP-BPI fusion protein with in vivo efficacy and longer half life.", JOURNAL OF ENDOTOXIN RESEARCH, vol. 2, June 1995 (1995-06-01), pages 209 - 212, XP000611392  
• See references of WO 9425476A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 9425476 A1 19941110**; AU 6942994 A 19941121; CA 2161971 A1 19941110; EP 0760849 A1 19970312; EP 0760849 A4 19961202; JP H08511682 A 19961210

DOCDB simple family (application)  
**US 9404709 W 19940429**; AU 6942994 A 19940429; CA 2161971 A 19940429; EP 94917901 A 19940429; JP 52455494 A 19940429